These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 36090976)

  • 1. Toxic epidermal necrolysis induced by sintilimab in a patient with advanced non-small cell lung cancer and comorbid pulmonary tuberculosis: A case report.
    Li G; Gong S; Wang N; Yao X
    Front Immunol; 2022; 13():989966. PubMed ID: 36090976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxic Epidermal Necrolysis and Stevens - Johnson Syndrome Following Sintilimab Administration in a Non-Small Cell Lung Cancer Patient: A Case Report.
    Jiang Z; Chen X; Sun Z; Shen X; Huang Y; Liu J
    J Inflamm Res; 2023; 16():5061-5067. PubMed ID: 37936597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxic epidermal necrolysis associated with chemoimmunotherapy for lymphoma: case report and literature review.
    Yang W; Xu X; Xia D; Wang H; Jiang J; Yang G
    Immunotherapy; 2022 Apr; 14(5):275-282. PubMed ID: 35128931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case Report: Toxic epidermal necrolysis associated with sintilimab in a patient with relapsed thymic carcinoma.
    Yang H; Ma Q; Sun Y; Zhang K; Xing Y; Li H
    Front Oncol; 2022; 12():1065137. PubMed ID: 36620577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lichenoid dermatitis following PD-1 inhibitor-induced toxic epidermal necrolysis: a case report and literature review.
    Zhang L; Wang L; Cheng Q; Lei X; Wu J; Chen N
    Immunotherapy; 2023 Oct; 15(15):1249-1256. PubMed ID: 37585673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutaneous Stevens Johnson - Toxic Epidermal Necrolysis Immunotherapy related Toxicities in Lung Cancer Patients.
    Alexandris D; Alevizopoulos N; Gakiopoulou H; Stavrinou N; Vourlakou C
    J Oncol Pharm Pract; 2022 Jul; 28(5):1276-1282. PubMed ID: 35038934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case of toxic epidermal necrolysis associated with lenvatinib and sintilimab therapy for intrahepatic cholangiocarcinoma.
    Gong Y; Mao J; Liu M; Gao J
    J Int Med Res; 2023 May; 51(5):3000605231173556. PubMed ID: 37211771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NeoSCORE II: three vs four cycles of neoadjuvant sintilimab + chemotherapy for squamous non-small-cell lung cancer.
    Zhang X; Shao M; Yao J; Zhao L; Li L; Chen M; Zhang Y; Liu H; Chen Z; Li B; Wu Z; Fan J; Qiu F
    Future Oncol; 2024 Jan; 20(3):121-129. PubMed ID: 38353107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxic epidermal necrolysis associated with pembrolizumab.
    Cai ZR; Lecours J; Adam JP; Marcil I; Blais N; Dallaire M; Belisle A; Mathieu A
    J Oncol Pharm Pract; 2020 Jul; 26(5):1259-1265. PubMed ID: 31810421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxic Epidermal Necrolysis Induced by Sintilimab: A Case Report.
    Lye YL; Shan B; Jia CH; Liu J; Hou J; Du WL; Feng R; Liang P
    Ann Dermatol; 2023 May; 35(Suppl 1):S100-S102. PubMed ID: 37853877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint inhibitor-induced myocarditis in lung cancer patients: a case report of sintilimab-induced myocarditis and a review of the literature.
    Bi H; Ren D; Wang Q; Ding X; Wang H
    Ann Palliat Med; 2021 Jan; 10(1):793-802. PubMed ID: 33545801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indirect comparison of sintilimab and other PD-L1 inhibitors for first-line treatment of non-squamous non-small-cell lung cancer.
    Zhang L; Qian Y; Li J; Cui C; Chen L; Qu S; Lu S
    Future Oncol; 2022 May; 18(15):1896-1905. PubMed ID: 35311347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of immune-related lichenoid dermatitis by Weiling decoction in a patient with non-small cell lung cancer: A case report and review of literature.
    Liu Y; Tang J; Yu LY; Jiang Q
    Explore (NY); 2023; 19(5):730-735. PubMed ID: 36878772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promising response to a PD-1 inhibitor (sintilimab) in non-small cell lung cancer: A case report.
    Zhang L; Mai W; Hao B; Jiang W; Geng Q
    Medicine (Baltimore); 2020 May; 99(21):e19790. PubMed ID: 32481252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sintilimab-induced erythema multiforme drug eruption in the treatment of sigmoid colon cancer: A case report and literature review.
    Zhang M; Wu R; Jia M; Sun S; Zhang L; Tang T
    Medicine (Baltimore); 2023 Oct; 102(41):e35659. PubMed ID: 37832081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adalimumab for Sintilimab-Induced Toxic Epidermal Necrolysis in a Patient with Metastatic Gastric Malignancy: A Case Report and Literature Review.
    Zhang L; Wu Z
    Clin Cosmet Investig Dermatol; 2023; 16():457-461. PubMed ID: 36846442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upper Gastrointestinal Tract IrAEs: A Case Report About Sintilimab-Induced Acute Erosive Hemorrhagic Gastritis.
    Ai Q; Chen W; Li Y; Li G
    Front Immunol; 2022; 13():840916. PubMed ID: 35720298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial experience of video-assisted thoracic surgery lobectomy after neoadjuvant chemotherapy plus toripalimab in a patient with locally advanced non-small cell lung cancer: a case report.
    Li W; Zhai C; Che J; Wang W; Liu B
    J Cardiothorac Surg; 2022 Jan; 17(1):10. PubMed ID: 35034650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case Report: sintilimab-induced Stevens-Johnson Syndrome in a patient with advanced lung adenocarcinoma.
    Li X; Li G; Chen D; Su L; Wang RP; Zhou Y
    Front Oncol; 2023; 13():912168. PubMed ID: 37781182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aprepitant for refractory nivolumab-induced pruritus.
    Ito J; Fujimoto D; Nakamura A; Nagano T; Uehara K; Imai Y; Tomii K
    Lung Cancer; 2017 Jul; 109():58-61. PubMed ID: 28577951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.